Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy.

about

Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy.

Item

http://www.wikidata.org/entity/Q43139088

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Evaluation of factors associat ...... reated with chemoradiotherapy.

@en

Evaluation of factors associat ...... reated with chemoradiotherapy.

@nl

type

Item

label

Evaluation of factors associat ...... reated with chemoradiotherapy.

@en

Evaluation of factors associat ...... reated with chemoradiotherapy.

@nl

prefLabel

Evaluation of factors associat ...... reated with chemoradiotherapy.

@en

Evaluation of factors associat ...... reated with chemoradiotherapy.

@nl

P1476

Evaluation of factors associat ...... reated with chemoradiotherapy.

@en

P2093

Jinming Yu

http://www.w3.org/2001/XMLSchema#string

Peng Xie

http://www.w3.org/2001/XMLSchema#string

Qiang Wen

http://www.w3.org/2001/XMLSchema#string

Shijiang Wang

http://www.w3.org/2001/XMLSchema#string

Xindong Sun

http://www.w3.org/2001/XMLSchema#string

Xue Meng

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials.

Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients.

Predictive and prognostic factors in small cell lung cancer: current status.

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer.

Is higher lactate an indicator of tumor metastatic risk? A pilot MRS study using hyperpolarized (13)C-pyruvate.

P304

81405-81418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19073

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29113400

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

P932

5655295

http://www.w3.org/2001/XMLSchema#string